Total Funding
33
1
Total FundingSeed raised
Growth Score
-7 pts
Heat Score
-10 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
598043
CYPRUMED is a biopharmaceutical company
Martin Werle: Chief Operating OfficerPast Role: Syngenta, Formulation Development, Corporate Strategy and Global R&D Project Management- Florian Föger: Founder & CEOPast Role: Novo Nordisk, Director of Oral Formulation Research
About the Company
CYPRUMED® is a biopharmaceutical company developing a next generation platform technology for the oral delivery of polypeptides. The patent pending technology is entirely based on GRAS listed compounds and easy to formulate. In vivo studies with various polypeptide drugs in rodents, dogs and none human primates showed oral bioavailability up to 70%
(rel. s.c.).
